Week 5 Assignment 1: Captain Of The Ship Obsessive Compulsiv

Week 5 Assignment 1 Captain Of The Shipobsessive Compulsivesss Univers

Describe the history of the present illness (HPI) and clinical impression for the client. Recommend psychopharmacologic treatments based on evidence-based practice and describe specific and therapeutic end points for your psychopharmacologic agent. (This should relate to HPI and clinical impression.). Recommend psychotherapy choices (individual, family, and group) and specific therapeutic endpoints for your choices. Identify medical management needs, including primary care needs, specific to this client. Identify community support resources (housing, socioeconomic needs, etc.) and community agencies that are available to assist the client. Recommend a plan for follow-up intensity and frequency and collaboration with other providers.

Paper For Above instruction

The management of schizophrenia spectrum and other psychotic disorders requires a comprehensive, patient-centered approach that combines pharmacological treatment, psychotherapy, medical management, and community support. Effective treatment planning involves a meticulous assessment of the patient's history, a clear diagnosis, and tailored interventions aimed at alleviating both positive and negative symptoms, enhancing functioning, and improving quality of life. This paper explores the clinical management of an adult client with a schizophrenia spectrum disorder, emphasizing evidence-based practices and collaborative care strategies.

History of Present Illness (HPI) and Clinical Impression

For this case, the client is an adult who presents with hallmark symptoms characteristic of schizophrenia spectrum disorder, including hallucinations, delusions, disorganized thinking, and negative symptoms such as social withdrawal and anhedonia. The HPI reveals recent onset of auditory hallucinations, with the client describing voices that comment on their actions and command behaviors, causing significant distress. The client also reports paranoid delusions involving surveillance and conspiracies, contributing to heightened anxiety and social isolation. Functional decline has been observed, with the client experiencing difficulty maintaining employment and social relationships. The clinical impression aligns with a diagnosis of schizophrenia, based on DSM-5 criteria, given the presence of active psychotic symptoms persisting for over six months, including at least one month of active symptoms and social/occupational dysfunction.

Psychopharmacologic Treatment Recommendations

Pharmacotherapy remains the cornerstone of treatment for schizophrenia spectrum disorders. Evidence supports the use of second-generation antipsychotics (SGAs) due to their efficacy and comparatively favorable side effect profiles. In this case, initiating treatment with risperidone, a widely studied SGA, is recommended. The initial dose of risperidone may be set at 2 mg daily, titrated gradually to an effective dose, typically between 4-6 mg daily, based on therapeutic response and tolerability. The goal is to reduce positive symptoms such as hallucinations and delusions, with a therapeutic endpoint being significant symptom reduction, improved insight, and overall stabilization of mood and behavior.

Monitoring parameters include assessment of symptom severity using validated scales such as the Positive and Negative Syndrome Scale (PANSS), side effects, weight, metabolic profile, and cardiac function, especially given the risk of QT prolongation. Therapeutic end points include remission of active psychotic symptoms, improved functioning, and minimal adverse effects. Regular follow-ups at weekly intervals initially, then bi-weekly or monthly once stabilized, ensure adequate monitoring and management of side effects.

Psychotherapy Modalities and Therapeutic Endpoints

Psychotherapeutic interventions are essential adjuncts to pharmacotherapy for comprehensive care. Cognitive Behavioral Therapy (CBT) for psychosis has demonstrated effectiveness in reducing symptom severity, improving adherence, and addressing secondary issues such as depression and anxiety. CBT can help the client challenge delusional beliefs, develop coping strategies for hallucinations, and improve insight. Family therapy aims to educate relatives about the disorder, reduce expressed emotion, and improve familial support, which correlates with better outcomes. Support groups and psychoeducation seminars provide additional community-based support, fostering social engagement and hope.

The therapeutic endpoints for psychotherapy include reduced severity and frequency of psychotic symptoms, enhanced social functioning, increased insight into the illness, and improved medication adherence. Successful therapy outcomes are also reflected in reduced hospitalization rates, improved quality of life, and enhanced personal and social functioning.

Medical Management Needs

Medical management involves comprehensive health monitoring to prevent and manage side effects associated with antipsychotic medications. Regular metabolic screening—including fasting glucose, lipid profile, and weight—is critical due to the risk of metabolic syndrome. Cardiac evaluation with baseline and periodic EKGs is necessary to monitor for QT prolongation risk associated with certain antipsychotics. Other medical issues include addressing comorbid conditions such as smoking, hypertension, cardiovascular disease, and potential substance use disorders.

Coordination with primary care providers ensures the holistic management of these health concerns. Patients should also receive vaccinations, screenings for cardiovascular risk factors, and health education to promote healthy lifestyle choices, including diet, exercise, and smoking cessation.

Community Support Resources

Community resources play a vital role in supporting clients with schizophrenia spectrum disorders. Housing assistance programs such as supportive housing and supervised apartments can provide stability and safety. Employment services tailored for individuals with mental health disorders can facilitate vocational rehabilitation. Psychoeducation groups, community mental health centers, and peer support groups contribute to social integration and resilience. Collaboration with agencies like the National Alliance on Mental Illness (NAMI) offers advocacy and education, empowering clients and families through resources and support networks. Additionally, social services can assist with financial aid, transportation, and legal issues, contributing to improved overall functioning.

Follow-up Plan and Collaboration

An effective follow-up plan involves scheduled visits at one to two-week intervals during the initial treatment phase, gradually extending to monthly assessments as stability improves. Monitoring symptom changes, medication adherence, side effects, and psychosocial functioning should be the focus of each visit. Interdisciplinary collaboration among psychiatrists, primary care providers, psychologists, social workers, and case managers ensures comprehensive and continuous care.

Regular communication, shared treatment plans, and coordinated interventions are essential to address emerging issues promptly. Engagement with community resources and support groups also forms part of the ongoing care plan. Family involvement, with the patient's consent, can reinforce treatment adherence and provide crucial support. Crisis plans should be established for acute exacerbations, including emergency contact information and contingency strategies.

Conclusion

Providing holistic, evidence-based management for clients with schizophrenia spectrum and other psychotic disorders enhances treatment outcomes and quality of life. Combining carefully selected pharmacotherapy, psychotherapy, thoughtful medical management, and robust community support creates a comprehensive framework that addresses both active symptoms and residual deficits. Interdisciplinary collaboration and consistent follow-up are fundamental to achieving sustained stability and functional recovery in these complex cases.

References

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
  • Gabbard, G. O. (2014). Gabbard’s treatment of psychiatric disorders (5th ed.). American Psychiatric Publishing.
  • Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th ed.). Cambridge University Press.
  • Fusar-Poli, P., et al. (2018). Preventive treatments for psychosis: A systematic review. Schizophrenia Bulletin, 44(1), 1–11.
  • Leucht, S., et al. (2017). Early use of antipsychotics for first-episode schizophrenia: An evidence-based review. CNS Drugs, 31(7), 565-579.
  • Kahn, R. S., & Keefe, R. S. (2013). Schizophrenia. The Lancet, 383(9929), 1576–1588.
  • Miyamoto, S., et al. (2012). Treating the negative symptoms of schizophrenia: A review of the evidence. Journal of Psychopharmacology, 26(12), 1333–1347.
  • Correll, C. U., et al. (2015). Pharmacological treatment of schizophrenia in children and adolescents: A systematic review. JAMA Psychiatry, 72(11), 1060–1068.
  • Kreyenbuhl, J., et al. (2010). Medication adherence in schizophrenia: Perspectives of patients, clinicians, and caregivers. Journal of Psychiatric Practice, 16(4), 222–231.
  • Sartorius, N., et al. (2014). Social interventions, living conditions, and mental health. World Psychiatry, 13(3), 339–341.

Related Assignments